Study design
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, superiority clinical trial, which conforms to the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement guidelines [24] and the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 Statement [25]. The study began in January 2016 and will last until October 2022. A total of 120 eligible patients will be enrolled and randomized into QCHS granule group or placebo group. All patients will voluntarily sign the informed consent prior to enrollment. Prior to allocation, each of them will be screened by the eligibility criteria. According to patients’ included sequence number equally, block randomization will be performed to ensure equal group sizes with an allocation of 1:1 (permuted block sizes of 6). Participants in QCHS granule group will receive QCHS granule (125 g, twice daily, orally) for continuous 12 weeks, while patients in placebo group will receive QCHS granule placebo (125 g, twice daily, orally) for the same duration. Both groups will be given basic treatment with mesalazine (5-aminosalicylic acid, 4 g/d). Researchers and patients will be blinded from the beginning of the trial. All interested outcomes including patient-reported outcomes will be collected before (0 week) and after intervention (2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks and 12 weeks). The whole study period will last 36 weeks, including 24 weeks of follow-up. The complete SPIRIT (2013) checklist for the study is provided in Additional file 1. The overview and the SPIRIT schedule of the study are illustrated in Figs. 1 and 2, respectively.
Study setting
This study was developed by research team in Nanjing (Jiangsu Province Hospital of Chinese Medicine) together with nine teams in China. The collaborators were selected based on the characteristics of sites as well as the strength and experience of their teams. As a result, patients will be recruited from 10 subcenters (tertiary hospitals) across China, including Affiliated Hospital of Nanjing University of Chinese Medicine, Beijing Hospital of Chinese Medicine, LongHua Hospital Shanghai University of Traditional Chinese Medicine, Guangdong Province Hospital of Chinese Medicine, The First Affiliated Hospital of Henan University of Chinese Medicine, ShengJing Hospital of China Medical University, Affiliated Hospital of Shanxi University of Chinese Medicine, The Second Affiliated Hospital of Fujian Traditional Chinese Medical University, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Nantong Hospital of Chinese Medicine. Each research institution will follow the same research protocol.
Ethics and registration
The protocol has been approved by Ethics Committee of Affiliated Hospital of Nanjing University of Chinese Medicine (approval number:2014NL-074-02, Additional file 2). Each sub-center applied for local institutional review boards (IRBs) approval. Furthermore, this trial has been registered on Chinese Clinical Trial Registry (URL: http://www.chictr.org.cn/, No. ChiCTR-IOR-14005554 ).
Sample size and power calculation
The sample size was calculated according to the primary outcome (clinical response rate) at 12 weeks after initiation. The sample size calculation was based on the comparison of the proportions in the QCHS granule group versus placebo group. On the basis of our previous studies, we predicted that the clinical remission rates at 12 weeks would be 79% in the QCHS granule group and 41 % in the placebo group. A difference of 10% was selected as the smallest difference that would be of clinical significance. For a two-sided significance level of 0.05 (α = 0.05), it is estimated that a sample size of 54 subjects per group will be required to detect the superiority of QCHS granule over placebo with a test power of 80%. Under the hypothesis that some patients are unable to follow-up or unsuitable for analysis, the sample size will be inflated. Considering 10% drop out, the total planned sample size will be 60 per group.
Randomization, allocation concealment and blinding
Each eligible patient will be randomly allocated into QCHS granule group (5-ASA+ QCHS granule) or control group (5-ASA+ QCHS granule placebo) with an allocation ratio of 1:1. Stratified block randomization (by site) will be performed to ensure equal group sizes with permuted blocks (block size of 6) . The randomization allocation sequence generated by SAS 9.4 (SAS Institute Inc., Cary, NC, USA) was converted into unique serial numbers for each enrolled subject in subcenters. QCHS granule and placebo granule will be provided to each subcenter in advance, encoded and labelled with above serial number. To ensure blinding, the QCHS granule and placebo granule will be identical in all aspects (e.g. appearance, size, color, smell, taste, containers and doses). Participant and Principal Investigators will be blinded to group allocation throughout the research. The randomization procedure was conducted by an independent research assistant who is not involved in clinical observation or assessment. Under the supervision of Data Safety and Monitoring Board (DSMB), the randomization code will only be broken due to adverse event and statistical analysis.
Participants
The participants will be 120 patients with moderately active UC.
Inclusion criteria
Patients will be included if they meet the following criteria:
1.Confirmed diagnosis of moderately active UC after taking 5-ASA for more than 4 weeks (total Mayo score between 6 and 10, Endoscopy subscore>2)
2.Confirmed diagnosis of TCM syndrome differentiation (large intestine damp-heat syndrome)
3.Males or females with age range between 18 and 50 years
4.Ethical principle who voluntarily sign the informed consent form
Exclusion criteria
Patients will be excluded if they have following criteria:
1.Patients with other intestinal diseases (e.g. bacterial dysentery, intestinal tuberculosis, Crohn's disease)
2.Patients with serious complications (e.g. intestinal perforation, intestinal obstruction, toxic megacolon, colorectal cancer)
3.Patients who are pregnant, breast-feeding, or preparing for pregnancy
4.Patients with significant cardiac disease, hepatic disease, pulmonary disease, renal disease and other serious diseases (abnormal urine protein, platelet value of less than 100 × 109 /l, alanine aminotransferase level above the upper limit of normal, leukocyte count of less than 4.0 × 109 /l)
5.Patients who have severe physical disability (e.g. blindness, deafness, dumbness, intellectual disability, mental disability, physical disability)
6.patients who have a history of alcohol or drug abuse
7.Patients who have a history of food allergy or drug allergy
8.Patients who are participating in other clinical trials
Withdrawal criteria
Patients who don’t meet the inclusion criteria, have no data after randomization, have never used research medication, take forbidden drugs will be withdrawn from this study.
Dropout criteria
Patients who are unable to be followed-up after informed consent and randomization will be considered dropout of our study.
Termination criteria
Patients will be terminated if they meet the following criteria:
1.Abnormality of safety index during treatment(ALT more than twice the upper limit of normal, Cr more than the upper limit of normal, platelet count less than 50 × 109 / L, white blood cells less than 3.0 × 109 / L
2.Worse condition during the course (bloody stools more than 6 times daily accompanied by body temperature> 37.8 ℃ or Hb <10.5 g / dL)
3. Significant biases occurred in clinical research
4. Poor compliance
Recruitment, screening and enrollment procedures
Each subcenter need to regularly discuss the protocol and its implementation so as to have a better understanding of the trial. Site-specific implementation plans were made respectively. Specialized subject recruitment advertisement was placed in the newspaper or on the social network platform. Furthermore, fliers and brochures regarding subject recruitment have been placed inside the hospital.
According to the above-mentioned inclusion and exclusion criteria, standardized screening form was implemented to identify the potential eligible participants. After the eligible subject has been confirmed, investigators will communicate with the patient face to face explaining the purpose of the trial as well as the trial procedures. Voluntarily, participants need to sign the informed consent form if they are willing to receive them.
Intervention
Basic treatment
During intervention period, all eligible patients with moderately active UC will receive standard treatment of Mesalazine Sustained Release Granules (5-aminosalicylic acid, 5-ASA, 4g/d, 4 times daily) produced by French IPSEN Pharmaceutical Factory.
QCHS granule group
Those patients randomized to the intervention group will receive Qing-Chang-Hua-Shi granule (QCHS, 125 g, twice daily, orally) additionally. This Chinese herbal prescription consists of several ingredients: Rhizoma Coptidis (Huanglian) 6 g, Radix Scutellariae (Huangqin) 10 g, Herba Patriniae (Baijiangcao) 15g, Angelicae Sinensis Radix (Danggui) 10g, Radix Paeoniae Alba (Baishao) 20 g, Radix Angelicae Dahuricae (Baizhi) 12 g, Radix Aucklandiae (Muxiang)6 g, Radix Sanguisorbae (Diyu) 10 g, Lithospermum Erythrorhizon (Zicao) 10 g, Rubia Cordifolia (Qiancao) 20 g, Licorice (Gancao) 6 g.
Control group
Patients in control group will be treated with 5-ASA plus QCHS granule placebo (125 g, twice daily, orally), which is similar to QCHS granule in terms of appearance, size, color, smell, taste, doses and containers.
According to the Good Agricultural Practice (GAP), all ingredients of Chinese herbal granule and placebo were manufactured by Jiangyin Tianjiang Pharmaceutical Co., Ltd, Jiangyin, China. Raw herbs were extracted in hot water, and the aqueous extract was concentrated, dried, and packed in sealed opaque packages. Instruction and code label will be tagged outside the container. Participants were asked to dissolve the granules by hot water and drink the mixture.
Study period
The total course of intervention is 12 weeks with 24 weeks follow-up. After Enrollment, the trial will last 36 weeks continuously.
Outcomes
The primary outcome of this study is the clinical response rate in patients with moderately active UC. The clinical response refers to a decrease (from the baseline) of the total Mayo score by at least 30% (or 3 point) together with a decrease of the rectal bleeding subscore by at least 1 point (or rectal bleeding subscore of 0 or 1 point) with no individual subscore exceeding 1 point [26].
The secondary outcomes are as follows: health-related quality of life measured by the inflammatory bowel disease questionnaire (IBDQ), endoscopic response rate defined as a decrease of Mayo disease activity index endoscopy subscore by at least 1 [26], mucosal healing rate defined as endoscopy subscore of Mayo disease activity index of 0 or 1, and improvements in inflammatory markers (e.g. Fecal calprotectin, Tumor necrosis factor -α and hypersensitive -C reactive protein, Erythrocyte sedimentation rate).
Additional information
In addition, information regarding biological index (e.g. demographic characteristics, vital signs) and diagnostic index (e.g. course, status, physiological and biochemical indicators) will be obtained at baseline and follow-up. Safety index will be observed throughout the study. During the study, adverse events (AEs) will be recorded on a standard SAE form and reported to the Institutional Review Board (IRB) of the Affiliated Hospital of Nanjing University of Chinese Medicine. Those patients who experienced SAEs will be followed up for detailed reports.
Data collecting and follow-up
According to the protocol, assessments will be repeated 7 times during the 12 weeks intervention: at baseline, at 2 weeks, at 4 weeks, at 6 weeks, at 8 weeks, at 10 weeks, at 12 weeks. For those patients who have been induced to remission at the end of the intervention, we will follow up for 24 weeks. After enrollment, participants will attend a total of thirteen trial visits. Participants who completed our trial will be provided with 400 RMB for transport compensation. At the beginning and the end of the study, Mayo score, colonoscopy, mucosal histology, heath-related quality of life, biochemical parameters, safety index will be measured. However, partial Mayo score, symptom indicators (e.g. diarrhea, bloody stools, and abdominal pain), biochemical parameters (e.g. Fecal calprotectin, hypersensitive-C reactive protein, Erythrocyte sedimentation rate, Stool routine, Occult blood test), safety index (e.g. blood routine, liver function and kidney function) will be evaluated at 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks respectively.
Data management and quality control
To ensure the quality of this trial, an external monitoring agency (a CRO located in Nanjing) will be hired to help data collection, management and analysis across all subcenters. All data will be recorded (double-entered) on electronic case report forms (eCRFs) by trained investigators and will be monitored monthly via electronic data capture system. For each abnormal or missing datum, a query will be automatically sent to the investigator. Once all the inconsistencies or queries are solved, the database will be locked for statistical analysis.
Statistical analysis
According to our protocol, all data analyses will be conducted based on pre-established statistical analysis plan. All analyses of data will be performed by SAS software (v. 9.3; SAS Institute Inc., Cary, NC, USA). To ensure the consistency and reliability of the conclusions, both Intention-To-Treat (ITT) analysis and Per-Protocol (PP) analysis will be done if necessary. All missing data will be imputed by multiple imputation. Statistical description will be performed with frequency, mean, median, standard deviation, lower quartile (P25), upper quartile (P75), minimum, maximum. Normality of all quantitative (continuous) variables (e.g. demographic characteristics, vital signs, biochemical parameters) will be tested by the Kolmogorov-Smirnov test. For normal distribution data, independent sample t-test and paired sample t-test will be employed to compare parameters at the beginning and the end of the study between and within groups, respectively. For abnormal distributions data (e.g. quality of life, inflammation markers), the Mann–Whitney U test and Wilcoxon signed-rank test will be used instead. For qualitative (categorical) variables, the chi-square test or Fisher’s exact test will be used, such as clinical response rate, endoscopic response rate and mucosal healing rate. In the evaluation of efficacy and analysis of influencing factors, center and disease will be used as covariates. Covariance analysis (ANCOVA) will be used. Multiple linear regression or logistic regression will be used to analyze the influencing factors and evalutate effect of gender and condition on the efficacy of the two groups. For all analyses, P < 0.05 will be considered statistically significant.